2012

FGFR1 amplification and the progression of non-invasive to invasive breast cancer

Alejandro A. Gru  
*Washington University School of Medicine in St. Louis*

D. Craig Allred  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [http://digitalcommons.wustl.edu/open_access_pubs](http://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**  
[http://digitalcommons.wustl.edu/open_access_pubs/1218](http://digitalcommons.wustl.edu/open_access_pubs/1218)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
FGFR1 amplification and the progression of non-invasive to invasive breast cancer

Alejandro A Gru* and D Craig Allred

See related research by Jang et al, http://breast-cancer-research.com/content/14/4/R115

Abstract
The incidence of invasive breast cancer (IBC) can be dramatically reduced by improving our abilities to detect and treat ductal carcinoma in situ (DCIS). Progress will be based on a detailed understanding of molecular mechanisms responsible for tumor progression. An interesting study by Jang and colleagues evaluated and compared the frequency of amplification of four oncogenes (HER2, c-MYC, CCND1, and FGFR1) in large cohorts of pure DCIS, in the DCIS component of IBC, and in corresponding IBC. Of particular interest, they found a twofold increase in FGFR1 amplification in IBC versus pure DCIS, and significantly reduced disease-free survival in amplified versus unamplified IBC—leading the authors to conclude that FGFR1 plays an important role in the development and progression of IBC. These observations indeed provide hints that FGFR1 is important in this setting, although the issue is very complex and far from resolved.

Invasive breast cancer (IBC) evolves through a series of increasingly abnormal premalignant stages, over decades in most cases [1,2]. Ductal carcinoma in situ (DCIS) is a late stage in this evolution and the immediate precursor for most IBC. Currently, about 60,000 new cases of DCIS are diagnosed in the USA each year [3]. If undetected, at least one-third of cases will progress to IBC [4]. About 200,000 cases of IBC are also diagnosed [3], and nearly all evolve from DCIS that was not detected.

The incidence of IBC can be dramatically reduced by improving our abilities to detect and successfully treat DCIS, which will be based on a detailed understanding of molecular mechanisms responsible for tumor progression.

Although there is much to learn, recent studies have begun to shed light on this important issue [5,6]. Among these is an interesting study by Jang and colleagues described in a recent issue of Breast Cancer Research, which evaluated and compared the frequency of amplification of four oncogenes (HER2, c-MYC, CCND1, and FGFR1) in large cohorts of pure DCIS (n = 175), in the DCIS component of IBC (n = 203), and in the corresponding IBC (n = 427) [1]. Amplification was carefully assessed by fluorescence in situ hybridization on tissue microarrays containing triplicate 2 mm cores/sample, which is far more tissue than used in most tissue microarray studies. Overall, they found reasonable rates of amplification for each oncogene in IBC consistent with many previous studies [7]. Far fewer studies of DCIS are available for comparison.

The main focus of the study was to compare amplification between pure DCIS and IBC, hypothesizing that differences may help identify genes that are important in the transition from in situ to invasive disease. In this regard, the most notable findings included significantly higher rates of HER2 amplification in pure DCIS versus IBC (31% vs. 20%; P = 0.004), which has been shown before [8], and significantly lower rates of FGFR1 in pure DCIS versus IBC (6% vs. 13%; P = 0.02), which is novel. These differences were more pronounced in lesions of high histological grade (HER2 60% vs. 34%; FGFR1 7% vs. 16%). Amplification frequencies in intrinsic molecular subtypes of IBC were also generally consistent with previous studies [7]. Jang and colleagues also looked at the relationship between amplification and clinical outcome. In these studies, amplification of FGFR1 was associated with significantly reduced disease-free survival in patients with IBC (about 10% at 8 years), particularly in hormone-receptor-positive patients, although HER2, c-MYC, and CCND1 were not prognostic in this cohort.

The twofold elevation of FGFR1 amplification in IBC versus pure DCIS, and the poor prognosis in IBC, led the authors to conclude that activation plays an important role in the progression of breast cancer, including, in particular, the in situ to invasive transition. This is a reasonable conclusion in the sense that it is also
consistent with previous studies showing that FGFR1 activation is oncogenic for breast cancer in transgenic mice [9], and is associated with increased invasion of breast cancer cell lines in vitro [10] and poor prognosis in IBC [7,11,12], especially in receptor-positive disease [11,12].

Although our understanding of FGFR1 at the molecular level is incomplete, important aspects are known about its function and the consequences of gene amplification [13]. For example, the gene encodes a tyrosine kinase receptor that is part of a large family of fibroblast growth factors and receptors. In a normal setting, activation of FGFR1 can lead to transactivation of mitogen-activated protein kinase and AKT, which collectively are essential for breast development, including the growth and differentiation of luminal epithelial cells. However, increased FGFR1 activity, such as occurs through gene amplification, can result in increased luminal cell proliferation and, in transgenic mouse models, this hyperplasia may eventually evolve into in situ and invasive mammary carcinomas.

In humans, the chromosomal region where FGFR1 resides, 8p11.2, is amplified in significant proportions of many types of cancers, including kidney cancer, lung cancer, prostate cancer, and leukemias. The region is also amplified in 10 to 20% of IBC [13]. However, the 8p11.2 amplicon is large and complex, and FGFR1 is only one of several candidate oncogenes within the region [14] – others include LSM1, PPAPDC1B, WHSC1LI, and BAG4, which are also important in breast development and cell cycle regulation, among other relevant functions. To complicate matters more, only about 50% of FGFR1-amplified tumors appear to overexpress the transcript [15].

The study by Jang and colleagues provides additional evidence of an important role for FGFR1 amplification in the progression of IBC [1]. The study also provides tantalizing hints that FGFR1 may be important in the in situ to invasive transition, which is a critical step in the progression of a nonlethal to potentially lethal disease – and this aspect of the study is entirely novel. Having said this, we need to be cautious about drawing conclusions regarding gene function and malfunction based on correlative studies of this nature alone. For example, the main evidence that FGFR1 is important in this study is elevated amplification in IBC versus DCIS. By analogous reasoning, the elevated amplification of HER2 observed in DCIS versus IBC could be taken as evidence for suppression of tumor progression, which we know is wrong. Determining the molecular function, oncogenic potential, and clinical significance of FGFR1 at any stage of breast cancer evolution will require many additional comprehensive laboratory and clinical studies. These studies are particularly worthwhile in the sense that we have effective drugs to inhibit FGFR1 activity [13]. Jain and Turner have summarized recent interesting data in terms of the functional biology of the fibroblast growth factor receptors and development of inhibitors of these molecules, with emphasis on challenges to successfully target this pathway in breast cancer [16]. These could lead to new strategies for preventing the progression of DCIS to IBC, or restoring responsiveness of receptor-positive IBC to endocrine therapy if activation is confirmed to induce resistance [11,12] – perhaps FGFR1 will be the next HER2.

Abbreviations
DCIS, ductal carcinoma in situ; FGFR1, fibroblast growth factor receptor 1; HER2, human epidermal growth factor receptor 2; IBC, invasive breast cancer.

Competing interests
The authors declare that they have no competing interests.

Published: 14 November 2012

References